Literature DB >> 31517562

Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: A potential mechanism for progression and exacerbation of COPD.

Keitaro Nakamoto1, Masato Watanabe1, Mitsuru Sada1, Toshiya Inui1, Masuo Nakamura1, Kojiro Honda1, Hiroo Wada1, Haruyuki Ishii1, Hajime Takizawa1.   

Abstract

Background and purpose of the study: Pseudomonas aeruginosa commonly colonizes the airway of patients with chronic obstructive pulmonary disease (COPD) and exacerbates their symptoms. P. aeruginosa carries flagellin that stimulates toll-like receptor (TLR)-5; however, the role of flagellin in the pathogenesis of COPD remains unclear. The aim of the study was to evaluate the mechanisms of the flagellin-induced innate immune response in bronchial epithelial cells, and to assess the effects of anti-inflammatory agents for treatment. Materials and methods: We stimulated BEAS-2B cells with P. aeruginosa-derived flagellin, and assessed mRNA expression and protein secretion of interleukin (IL)-6 and IL-8. We also used mitogen-activated protein kinases (MAPK) inhibitors to assess the signaling pathways involved in flagellin stimulation, and investigated the effect of clinically available anti-inflammatory agents against flagellin-induced inflammation.
Results: Flagellin promoted protein and mRNA expression of IL-6 and IL-8 in BEAS-2B cells and induced phosphorylation of p38, ERK, and JNK; p38 phosphorylation-induced IL-6 production, while IL-8 production resulted from p38 and ERK phosphorylation. Fluticasone propionate (FP) and dexamethasone (DEX) suppressed IL-6 and IL-8 production in BEAS-2B cells, but clarithromycin (CAM) failed to do so. Conclusions: P. aeruginosa-derived flagellin-induced IL-6 and IL-8 production in bronchial epithelial cells, which partially explains the mechanisms of progression and exacerbation of COPD. Corticosteroids are the most effective treatment for the suppression of flagellin-induced IL-6 and IL-8 production in the bronchial epithelial cells.

Entities:  

Keywords:  BEAS-2B cells; MAPKs; clarithromycin; dexamethasone; fluticasone propionate

Mesh:

Substances:

Year:  2019        PMID: 31517562     DOI: 10.1080/01902148.2019.1665147

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  5 in total

1.  Roseburia intestinalis‑derived flagellin ameliorates colitis by targeting miR‑223‑3p‑mediated activation of NLRP3 inflammasome and pyroptosis.

Authors:  Xing Wu; Shiyu Pan; Weiwei Luo; Zhaohua Shen; Xiangrui Meng; Mengwei Xiao; Bei Tan; Kai Nie; Ting Tong; Xiaoyan Wang
Journal:  Mol Med Rep       Date:  2020-07-23       Impact factor: 2.952

2.  Identification of biomarkers associated with clinical severity of chronic obstructive pulmonary disease.

Authors:  Jie Zhang; Changli Zhu; Hong Gao; Xun Liang; Xiaoqian Fan; Yulong Zheng; Song Chen; Yufeng Wan
Journal:  PeerJ       Date:  2020-12-10       Impact factor: 2.984

3.  Oral Pathogen Fusobacterium nucleatum Coaggregates With Pseudomonas aeruginosa to Modulate the Inflammatory Cytotoxicity of Pulmonary Epithelial Cells.

Authors:  Qian Li; Hongyan Wang; Lisi Tan; Shuwei Zhang; Li Lin; Xiaolin Tang; Yaping Pan
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

4.  Rapid Synergistic Biofilm Production of Pseudomonas and Candida on the Pulmonary Cell Surface and in Mice, a Possible Cause of Chronic Mixed Organismal Lung Lesions.

Authors:  Pornpimol Phuengmaung; Jiradej Mekjaroen; Wilasinee Saisorn; Tanittha Chatsuwan; Poorichaya Somparn; Asada Leelahavanichkul
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

5.  The Fusion Protein rFlaA:Betv1 Modulates DC Responses by a p38-MAPK and COX2-Dependent Secretion of PGE2 from Epithelial Cells.

Authors:  Yen-Ju Lin; Adam Flaczyk; Sonja Wolfheimer; Alexandra Goretzki; Annette Jamin; Andrea Wangorsch; Stefan Vieths; Stephan Scheurer; Stefan Schülke
Journal:  Cells       Date:  2021-12-04       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.